Axxam executes a transaction with Acousia Therapeutics GmbH
December, 14th 2016 – Axxam is proud to announce the closing of a transaction with Acousia Therapeutics GmbH, by which Axxam becomes a shareholder of Acousia and Dr. Stefan Lohmer, Chairman and Chief Executive Officer of Axxam, joins the Board of Directors of the company. The new investment round of EUR 2.5 million, led by the Boehringer Ingelheim Venture Fund and supported by Axxam and the KfW, will finance research programs directed towards the development of small molecules to treat sensorineural hearing loss and protecting sensory hair cells of the inner ear to prevent hearing loss in at-risk patients. In connection with this new investment Axxam will also transfer certain therapeutic assets to the R&D programs of Acousia. For more info please open the Press Release from Acousia.